Effect of uric-acid-lowering therapy on progression of chronic kidney disease: A meta-analysis

Abstract

The efficacy and safety of uric-acid-lowering therapy (UALT) on slowing the progression of chronic kidney disease (CKD) accompanied by hyperuricemia were assessed. We searched Cochrane Library, PubMed, EMbase, CNKI, Wanfang and Vip databases up to November 15, 2012 for randomized controlled trials (RCTs) which compared the effect of UALT to control therapy in hyperuricemic patients secondary to CKD, and then performed quality evaluation and meta-analysis on the included studies. Seven RCTs involving 451 cases were included. UALT delayed the increase of serum creatinine (MD=−62.55 μmol/L, 95% CI: −98.10 to −26.99) and blood urea nitrogen (MD= −6.15 mmol/L, 95% CI: −8.17 to −4.13) as well as the decrease of glomerular filtration rate [MD=5.65 mL/(min·1.73 m2), 95% CI: 1.88 to 9.41], decreased systolic blood pressure (SBP) (MD= −6.08 mmHg, 95% CI: −11.67 to −0.49), and reduced the risk of the renal disease progression (RR=0.30, 95% CI: 0.19 to 0.46). However, there was no statistically significant difference in 24-h urinary protein quantity and diastolic blood pressure (P>0.05). We identified that UALT could delay the progression of CKD with secondary hyperuricemia. And this also indirectly proved that hyperuricemia was a risk factor for the CKD progression.

Keywords

hyperuricemia / chronic kidney disease / uric-acid-lowering / meta-analysis

References

[1] SchlesingerN, MooreDF, SunJD, et al.. A survey of current evaluation and treatment of gout. J Rheumatol, 2006, 33(10): 2050-2052

[2] NakayaI, NamikoshiT, TsurutaY, et al.. Management of asymptomatic hyperuricemia in patients with chronic kidney disease by Japanese nephrologists: A questionnaire survey. Nephrology (Carlton), 2011, 16(5): 518-521

[3] SonodaH, TakaseH, DohiY, et al.. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol, 2011, 33(4): 352-357

[4] Ben-DovIZ, KarkJD. Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study. Nephrol Dial Transplant, 2011, 26(8): 2558-2566

[5] ChangHY, TungCW, LeePH, et al.. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci, 2010, 339(6): 509-515

[6] BellomoG, VenanziS, VerduraC, et al.. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis, 2010, 56(2): 264-272

[7] SatirapojB, SupasyndhO, ChaiprasertA, et al.. Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population. Nephrology (Carlton), 2010, 15(2): 253-258

[8] TomitaM, MizunoS, YamanakaH, et al.. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol, 2000, 10(6): 403-409

[9] HigginsJ, AltmanDG. HigginsJ, GreenS. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1, 2008, Oxford, Cochrane Collaboration

[10] SiuYP, LeungKT, TongMK, et al.. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis, 2006, 47(1): 51-59

[11] LiuJ, ShengD. Allopurinol in lowering serum uric acid level for the delay of the progression of chronic renal disease. China Pharmac, 2007, 18(32): 2524-2525

[12] ZhouDY, ZhaoYJ, XiaoX, et al.. Treatment of hyperuricemia in chronic kidney disease patients and its effect. Mod Med J China (Chinese), 2009, 11(7): 36-39

[13] LeiJ, LiST. Clinical research on allopurinol lowering of uric acid level of chronic renal disease patients for the delay of the progression of renal disease. Shanxi Med J (Chinese), 2009, 38(9): 1191-1192

[14] DengYH, ZhangP, LiuH, et al.. Research on lowering serum uric acid with allopurinol to delay the progression of chronic kidney disease. J Pract Med (Chinese), 2010, 26(6): 982-984

[15] ShenH, LiuDY. Clinical research on allopurinol in lowering serum uric acid level for the delay of the progression of chronic renal disease. China Foreign Med Treat (Chinese), 2010, 13(12): 88-89

[16] GoicoecheaM, de VinuesaSG, VerdallesU, et al.. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol, 2010, 5(8): 1388-1393

[17] PacherP, NivorozhkinA, SzabóC. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev, 2006, 58(1): 87-114

[18] ChoncholM, ShlipakMG, KatzR, et al.. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis, 2007, 50(2): 239-247

[19] RuilopeLM, Garcia-PuigJ. Hyperuricemia and renal function. Curr Hypertens Rep, 2001, 3(3): 197-202

[20] JaramilloM, GodboutM, NaccachePH, et al.. Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J Biol Chem, 2004, 279(50): 52 797-52 805

[21] Sancher-LozadaLG, TapiaE, SantamariaJ, et al.. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int, 2005, 67(1): 237-247

[22] KangDH, NakagawaT, FengL, et al.. A role for uric acid in the progression of renal disease. J Am Soc Nephrol, 2002, 13(12): 2888-2897

[23] ConventoMS, PessoaE, DalboniMA, et al.. Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage. Urol Res, 2011, 39(1): 21-27

[24] KanellisJ, WatanabeS, LiJH, et al.. Uric acid stimulates MCP-1 production in vascular smooth muscle cells via MAPK and COX-2. Hypertension, 2003, 41(6): 1287-1293

[25] RoncalCA, MuW, CrokerB, et al.. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol, 2007, 292(1): F116-F122

[26] KarbowskaA, BoratynskaM, KusztalM, et al.. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transplant Proc, 2009, 41(8): 3052-3055

[27] Sánchez-LozadaLG, TapiaE, Avila-CasadoC, et al.. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol, 2002, 283(5): F1105-F1110

[28] KhoslaUM, ZharikovS, FinchJL, et al.. Hyperuricemia induces endothelial dysfunction. Kidney Int, 2005, 67(5): 1739-1742

[29] MazzaliM, KanellisJ, HanL, et al.. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol, 2002, 282(6): F991-F997

[30] WatanabeS, KangDH, FengL, et al.. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension, 2002, 40(3): 355-360

[31] CorryDB, EslamiP, YamamotoK, et al.. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens, 2008, 26(2): 269-275